Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Anthropic Nears $800 Billion Valuation as Investor Confidence Surges 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
WORCESTER, Mass., April 05, 2016 -- Nemucore Medical Innovations, Inc., a privately held, clinical-stage biopharmaceutical company dedicated to the development of therapies targeting multi-drug resistant cancers with a special emphasis on highly lethal women’s cancers, announced today that Timothy P. Coleman, President and Chief Executive Officer, will present a corporate overview and update at the Needham & Company’s 15th Annual Healthcare Conference on April 12-13, 2016 in New York City. The Nemucore presentation will take place at 09:20 AM on Wednesday, April 13, 2016.
About Nemucore Medical Innovations, Inc.
Nemucore Medical Innovations, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to the development of therapies targeting multi-drug resistant cancers with a special emphasis on highly lethal women’s cancers. Nemucore's most advanced candidate NMI-900, a potential "best-in-class" therapeutic for the treatment of ovarian cancer, is expected to begin a Phase 2b clinical trial in late-2016. Two additional candidates are anticipated to enter clinical trial development later in 2017, targeting a variety of difficult-to-treat oncology indications, including breast, non-small cell lung cancer (NSCLC), myelodysplastic syndrome (MDS) and other cancers. For more information, please visit our website at www.Nemucore.com.
Contacts: Tim Coleman (investors) Nemucore Medical Innovations (508) 762-1017 BCC Partners (media) Karen L. Bergman (650) 575-1509 [email protected] Jen LaVin (207) 360-0473 [email protected]
